| Co‐ordinate regulation of Salmonella typhimurium invasion genes by environmental and regulatory factors is mediated by control of hilA expression V Bajaj, RL Lucas, C Hwang, CA Lee Molecular microbiology 22 (4), 703-714, 1996 | 656 | 1996 |
| hilA is a novel ompR/toxR family member that activates the expression of Salmonella typhimurium invasion genes V Bajaj, C Hwang, CA Lee Molecular microbiology 18 (4), 715-727, 1995 | 485 | 1995 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 474 | 2021 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 304 | 2021 |
| Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer MG Sanda, DC Smith, LG Charles, C Hwang, KJ Pienta, J Schlom, ... Urology 53 (2), 260-266, 1999 | 253 | 1999 |
| Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM D Kong, E Heath, W Chen, ML Cher, I Powell, L Heilbrun, Y Li, S Ali, ... PloS one 7 (3), e33729, 2012 | 247 | 2012 |
| Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised … T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ... The lancet oncology 23 (9), 1133-1144, 2022 | 189 | 2022 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 183 | 2021 |
| Overcoming docetaxel resistance in prostate cancer: a perspective review C Hwang Therapeutic advances in medical oncology 4 (6), 329-340, 2012 | 176 | 2012 |
| Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment D Kong, E Heath, W Chen, M Cher, I Powell, L Heilbrun, Y Li, S Ali, ... American journal of translational research 4 (1), 14, 2012 | 97 | 2012 |
| Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis MS Congzhou, EJ Lehrer, C Hwang, DM Trifiletti, HB Mackley, JJ Drabick, ... Radiotherapy and Oncology 151, 141-148, 2020 | 88 | 2020 |
| Angiogenesis inhibitors in the treatment of prostate cancer C Hwang, EI Heath Journal of hematology & oncology 3 (1), 26, 2010 | 72 | 2010 |
| EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor C Hwang, VN Giri, JC Wilkinson, CW Wright, AS Wilkinson, KA Cooney, ... Breast cancer research and treatment 107, 235-242, 2008 | 59 | 2008 |
| Cytoprotective effects of IAPs revealed by a small molecule antagonist S Galbán, C Hwang, JM Rumble, KA Oetjen, CW Wright, A Boudreault, ... Biochemical Journal 417 (3), 765-771, 2009 | 58 | 2009 |
| Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells MM Taj, RJ Tawil, LD Engstrom, Z Zeng, C Hwang, MG Sanda, ... The Prostate 47 (3), 194-204, 2001 | 56 | 2001 |
| Efficacy and safety of autologous dendritic cell–based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: The … NJ Vogelzang, TM Beer, W Gerritsen, S Oudard, P Wiechno, ... Jama Oncology 8 (4), 546-552, 2022 | 52 | 2022 |
| Racial disparities in COVID-19 outcomes among black and white patients with cancer J Fu, SA Reid, B French, C Hennessy, C Hwang, NT Gatson, N Duma, ... JAMA network open 5 (3), e224304-e224304, 2022 | 50 | 2022 |
| Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen YC Xie, C Hwang, W Overwijk, Z Zeng, MH Eng, JJ Mulé, MJ Imperiale, ... Journal of the National Cancer Institute 91 (2), 169-175, 1999 | 50 | 1999 |
| Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide AB Pilling, C Hwang The Prostate 79 (11), 1347-1359, 2019 | 44 | 2019 |
| Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19 AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, ... JAMA network open 4 (11), e2134330-e2134330, 2021 | 42 | 2021 |
Mani MenonProfessor of Urology在 mountsinai.org 的电子邮件经过验证
